BioTuesdays

Anavex gets orphan drug status for infantile spasms

Anavex Life Sciences (NASDAQ:AVXL) has received FDA orphan drug designation for ANAVEX 2-73 for the treatment of infantile spasms.

ANAVEX 2-73 already has orphan drug designation for the treatment of Rett syndrome.

An infantile spasm is a specific type of seizure seen in an epilepsy syndrome of infancy and childhood known as West Syndrome. Infantile spasms occur in roughly two-to-three per 10,000 live births, with peak incidence at six months of age and less than 10% of cases presenting after 12 months of age. Children with symptomatic spasms more frequently exhibit neurological deficits and cognitive and developmental delays.

Subscribe

Sign up to our weekly BioTuesdays newsletter.

Subscribe

Sign up to our weekly BioTuesdays newsletter.